Institut Pasteur Korea – Hakim Djaballah, CEO
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
Institut Pasteur Korea is conceptualized around the virtual “genome to drugs” pipeline. The goal of IP-Korea is to actively implement post-genomic approaches into accelerated drug discovery. Accordingly, IP-Korea is situated at the very fault line between basic research and application.
The positioning of our institute is in good accordance with the Pasteurian tradition and mission. During its long history Institut Pasteur in Paris has been able to combine scientific achievements with their application in public health. This has improved the lives of millions of patients over the last 130 years, and has earned Institut Pasteur 10 Nobel prizes.
To extend and build on these achievements, IP-Korea is the first to develop a technology-based approach to therapeutic development in the areas of infectious and chronic diseases.
Strategically it combines its strength in biomedical research with Korean expertise in Information and Chemical technologies.
The result is the consequent implementation of visualization and imaging technology in analyzing disease models, accelerating both drug discovery and basic research.
Contact details
Address: 16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
Tel: +82 31 8018 8000
Fax: +82 31 8018 8010
Email: ipkorea@ip-korea.org
www.ip-korea.org
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
Please introduce the Korean Food and Drug Administration (KFDA) and its main health-related responsibilities within the Korean government… The KFDA’s main duty is to cooperate and support with domestic and…
How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the…
You have a very long track record working with Novo Nordisk in Asia. What is your perspective on the Diabetes explosion that has been taking place in this part of…
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector…
You are one of the foreign multinational directors with most time in the Korean pharmaceutical industry, since 2003. What is your assessment of the direction the market has taken in…
What is KHIDI’s role in supporting the development of the Korean health industry? KHIDI performs three major roles in supporting the Korean health industry, which includes pharmaceuticals, medical devices, cosmetics,…
Previous to your current position as President of Pfizer Korea since 2004, you had been in the country between 1989 and 1993 as sales and marketing director. How different are…
Please introduce Handok Pharmaceuticals to our readers, and in particular how it has evolved through partnerships with different multinational companies throughout its history. Handok has developed in a very unique…
Korea had a late start, but is now one of the global hot spots for clinical trials. How would you sum up and explain this quick evolution? Clinical trials in…
Already an economic powerhouse thriving on export-driven industries such as electronics, automotive and ship-building, South Korea is now looking to boost its potential in the life sciences and to…
Over the last several years we have seen a shift in clinical research from traditional healthcare markets to Asia. How do you see this trend evolving in the coming years?…
See our Cookie Privacy Policy Here
